Clinical Trials
26,883 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT02231749 2026-05-27
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT02386800 2026-05-27
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
NCT02477696 2026-05-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03899155 2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT04529122 2026-05-27
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
Hoffmann-La Roche
Completed
NCT04704934 2026-05-27
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT04720157 2026-05-27
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT04862663 2026-05-27
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT04928846 2026-05-27
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 3 Recruiting
NCT04938817 2026-05-27
KEYNOTE-B98
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04958239 2026-05-27
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT04980495 2026-05-27
ADAPT NXT
argenx
Phase 3 Completed
NCT05006716 2026-05-27
CaDAnCe-101
BeOne Medicines
Phase 1/2 Recruiting
NCT05015608 2026-05-27
SACHI
Hutchmed
Phase 3 Completed
NCT05052801 2026-05-27
FORTITUDE-101
Amgen
Phase 3 Completed
NCT05068102 2026-05-27
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05100056 2026-05-27
BV-MAZOVIA
Takeda
Recruiting
NCT05100862 2026-05-27
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT05176483 2026-05-27
STELLAR-002
Exelixis
Phase 1 Recruiting
NCT05181462 2026-05-27
TRIFOUR
Cantargia AB
Phase 1/2 Completed
NCT05249426 2026-05-27
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05384626 2026-05-27
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT05456191 2026-05-27
ASC4START
Novartis
Phase 3 Active not recruiting
NCT05519085 2026-05-27
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT05562830 2026-05-27
MK-3475-04A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05700448 2026-05-27
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals
Phase 3 Not yet recruiting
NCT05710848 2026-05-27
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
SURGE Therapeutics
Phase 1/2 Recruiting
NCT05839626 2026-05-27
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1 Terminated
NCT05849298 2026-05-27
PSMACare
Novartis
Phase 2 Active not recruiting
NCT05870579 2026-05-27
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Novartis
Phase 1 Recruiting
NCT05887011 2026-05-27
PASSAT
AstraZeneca
Active not recruiting
NCT05910827 2026-05-27
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Phase 1/2 Recruiting
NCT05939414 2026-05-27
PSMA-DC
Novartis
Phase 3 Recruiting
NCT06012435 2026-05-27
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT06068049 2026-05-27
OSIREAL
AstraZeneca
Recruiting
NCT06077500 2026-05-27
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06079671 2026-05-27
eVOLVECervical
AstraZeneca
Phase 3 Recruiting
NCT06120283 2026-05-27
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06120491 2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3 Active not recruiting
NCT06132113 2026-05-27
DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
Phase 1 Recruiting
NCT06136650 2026-05-27
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06137118 2026-05-27
SYRUS
AstraZeneca
Phase 1/2 Recruiting
NCT06158841 2026-05-27
CERVINO
AbbVie
Phase 3 Recruiting
NCT06225596 2026-05-27
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2 Active not recruiting
NCT06247995 2026-05-27
NeoB-Cap1
Novartis
Phase 1/2 Recruiting
NCT06248411 2026-05-27
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Recruiting
NCT06266143 2026-05-27
A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer
Wuhan YZY Biopharma Co., Ltd.
Phase 1/2 Completed